Quality of Life (QoL) with Lanreotide Autogel/Depot (LAN) vs. Placebo in Patients with Enteropancreatic Neuroendocrine Tumors: Results From the CLARINET Core Study

被引：0
|
作者：
Ruszniewski, Philippe [1 ]
Phan, Alexandria T. [2 ]
Caplin, Martyn E. [3 ]
Pavel, Marianne E. [4 ]
Cwikla, Jaroslaw B. [5 ]
Raderer, Markus [6 ]
Sedlackova, Eva [7 ,8 ]
Cadiot, Guillaume [9 ]
Wall, Lucy [10 ]
Rindi, Guido [11 ]
Langley, Alison [12 ]
Gomez-Panzani, Edda [13 ]
机构：
[1] Beaujon Hosp, Clichy, France
[2] Houston Methodist Hosp, Ctr Canc, Houston, TX USA
[3] Royal Free Hosp, London NW3 2QG, England
[4] Charite, D-13353 Berlin, Germany
[5] Univ Varmia & Masuria, Fac Med Sci, Olsztyn, Poland
[6] Univ Hosp Vienna, Vienna, Austria
[7] Fac Med 1, Prague, Czech Republic
[8] Gen Teaching Hosp, Prague, Czech Republic
[9] Hop Robert Debre, Reims, France
[10] Western Gen Hosp, Edinburgh EH4 2XU, Midlothian, Scotland
[11] Univ Cattolica Sacro Cuore, Rome, Italy
[12] Ipsen, Les Ulis, France
[13] Ipsen Biopharmaceut Inc, Basking Ridge, NJ USA
来源：
PANCREAS | 2015年 / 44卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：357 / 357
页数：1
相关论文
共 50 条
  • [1] Antitumor Effects With Lanreotide Autogel/Depot (LAN) in Patients With Metastatic Enteropancreatic (EP) Neuroendocrine Tumors (NETs): Interim Results of the CLARINET Extension Study
    Caplin, Martyn E.
    Phan, Alexandria T.
    Ruszniewski, Philippe
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    PANCREAS, 2015, 44 (02) : 351 - 352
  • [2] QUALITY OF LIFE (QOL) WITH LANREOTIDE DEPOT (LAN) VS PLACEBO IN PATIENTS WITH PANCREATIC AND GASTROINTESTINAL NEUROENDOCRINE TUMOURS: RESULTS FROM THE CLARINET PHASE III STUDY.
    Iwasaki, Michiko
    Phan, Alexandria
    Caplin, Martyn
    Ruszniewski, Philippe
    Pavel, Marianne
    Gomez-Panzani, Edda
    ONCOLOGY NURSING FORUM, 2015, 42 (02) : E144 - E144
  • [3] Lanreotide depot/autogel (LAN) in midgut neuroendocrine tumors (NETs): A subgroup analysis from the CLARINET study
    Dasari, A.
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] Effects of lanreotide autogel/depot (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [5] Lanreotide depot/autogel (LAN) in pancreatic neuroendocrine tumors (pNETs): A subgroup analysis from the CLARINET study.
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [6] Lanreotide Depot/Autogel in Neuroendocrine Tumors: Subgroup Analyses From the CLARINET Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 6 - 8
  • [7] Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged ≤65 vs. >65 years: Subgroup analyses from the CLARINET study.
    Dasari, A.
    Phan, Alexandria T.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Wolin, Edward M.
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] Lanreotide Depot/Autogel (LAN) Vs. Placebo (PBO) for Carcinoid Syndrome (CS) in Patients With Neuroendocrine Tumors (NETs): Subgroup Analysis of the ELECT Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2015, 13 (08) : 10 - 11
  • [9] Prognostic factors for progression-free survival (PFS) in CLARINET study of lanreotide depot/autogel (LAN) vs placebo (PBO) in neuroendocrine tumors (NETs).
    Wolin, Edward M.
    Caplin, Martyn E.
    Pavel, Marianne E.
    Cwikla, Jaroslaw B.
    Phan, Alexandria T.
    Raderer, Markus
    Sedlackova, Eva
    Cadiot, Guillaume
    Capdevila, Jaume
    Wall, Lucy
    Rindi, Guido
    Langley, Alison
    Gomez-Panzani, Edda
    Ruszniewski, Philippe B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Lanreotide depot/autogel (LAN) vs. placebo (PBO) for carcinoid syndrome (CS) in patients with neuroendocrine tumors (NETs): Subgroup analysis of the ELECT study
    Vinik, Aaron
    Wolin, Edward M.
    Audry, Helene
    Gomez-Panzani, Edda
    Fisher, George A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
12345